## Who Can Be Treated With PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) **Under The Emergency Use Authorization?**

PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.

The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.




Fact Sheet for Healthcare Providers

Fact Sheet for Patients, Parents, and Caregivers

FDA Emergency Use Authorization Letter






What is the patient's **risk** for progression to severe COVID-19?

High risk Standard risk

For more information on potential risk factors for severe illness or complications, see CDC guidance here. This link leads to a website that is owned and operated by CDC. Pfizer is not responsible for the content or maintenance of this site.



The 5-day treatment course of PAXLOVID should be initiated as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset.



Consult the Fact Sheet for Healthcare Providers for comprehensive information.



## Important Dosing Information in Patients with Renal Impairment

No dosage adjustment is needed in patients with **mild** renal impairment (eGFR ≥60 to <90 mL/min). In patients with moderate renal impairment (eGFR ≥30 to <60 mL/min), the dosage of PAXLOVID is 150 mg nirmatrelvir and 100 mg ritonavir twice daily for 5 days. Prescriptions should specify the numeric dose of each active ingredient within PAXLOVID. Providers should counsel patients about renal dosing instructions.

PAXLOVID is not recommended in patients with severe renal impairment (eGFR <30 mL/min) until more data are available; the appropriate dosage for patients with severe renal impairment has not been determined.



© 2022 Pfizer Inc. All rights reserved.

## Important Information Related to Drug Interactions

In the EUA Fact Sheet for Healthcare Providers, you'll find a table for clinically significant drug interactions, including contraindicated drugs. This table contains drug classes in alphabetical order, drugs within each class, their effect on concentration of concomitant medications or PAXLOVID, and clinical comments. The clinical comments provide potential adverse events that may result for an interaction and provide recommendations, where applicable, to manage these drug interactions. Drugs listed in the table are a guide and not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult appropriate references for comprehensive information.

National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. Available at: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ Centers for Disease Control and Prevention. Assessing Risk Factors for Severe COVID-19 Illness. Available at: https://www.cdc.gov/coronavirus/

2019-ncov/covid-data/investigations-discovery/assessing-risk-factors.html

